Results 71 to 80 of about 3,791 (213)

Impact of administered amount of peptide on tumor dosimetry at the first cycle of peptide receptor radionuclide therapy (PRRT) in relation to total tumor somatostatin receptor expression

EJNMMI Research, 2023
Background The accumulation of 177Lu-DOTATATE might be influenced by the amount of administered peptide in relation to the tumor somatostatin receptor expression.
Ulrika Jahn, Ulrike Garske-Román, Mattias Sandström, Mark Lubberink, Anders Sundin   +4 more
doaj   +1 more source

Primary Neuroendocrine Carcinoma of the Breast: A Diagnostic Challenge and Case Report

Cancer Reports, Volume 9, Issue 5, May 2026.
ABSTRACT Background Primary neuroendocrine carcinoma of the breast (NECB) represents an exceedingly rare entity, comprising less than 0.5% of all breast carcinomas and approximately 1% of all neuroendocrine neoplasms. The 2019 WHO classification defines NECB as tumors expressing neuroendocrine markers in > 90% of tumor cells with morphological features
Hamid Zeinali Nezhad, Shima Yaghoobi, Nazanin Zeinali Nezhad, Amirhossein Shahpar, Abtin Malekpour Afshar, Mina Bagherijamebozorgi   +5 more
wiley   +1 more source

Preclinical Lutetium-177 Intracellular Dosimetry of Target Cancers in Radionuclide Therapy

Journal of Medical Physics
Purpose: This study investigates the preclinical dosimetry of Lutetium-177 in targeted radionuclide therapy for cancer treatment, focusing on the radiopharmaceutical [177Lu] Lu-DOTATATE.
Aleksandr S. Lunev, Kristina A. Petrosova, Kristina E. Ternovskaya, Alexandra E. Zakharkina, Aleksandra I. Nigmatulina   +4 more
doaj   +1 more source

Survival outcomes and prognostic factors of gastric carcinoma with neuroendocrine differentiation

International Journal of Cancer, Volume 158, Issue 9, Page 2209-2218, 1 May 2026.
What's new? Although gastric carcinoma with neuroendocrine differentiation (GCNED) is associated with more aggressive features than conventional GC, its prognosis and survival remain poorly defined. To better understand survival patterns, the authors of the present study examined clinicopathological and prognostic features of GCNED patients following ...
Jinjin Li, Chenglong Wang, Yifan Shen, Zhen Huang, Jun Zhang, Siqi Rao, Youde Cao, Jiang Min   +7 more
wiley   +1 more source

Lutetium-177 DOTATATE Production with an Automated Radiopharmaceutical Synthesis System [PDF]

Asia Oceania Journal of Nuclear Medicine and Biology, 2015
Objective(s): Peptide Receptor Radionuclide Therapy (PRRT) with yttrium-90 (90Y) and lutetium-177 (177Lu)-labelled SST analogues are now therapy option for patients who have failed to respond to conventional medical therapy.
Alireza Aslani, Graeme Snowdon, Dale Bailey, Geoffrey Schembri, Elizabeth Bailey, Pavlakis Nick, Paul Roach   +6 more
doaj  

Impact of partial volume correction on radiomics reproducibility in theranostic SPECT/CT imaging

Medical Physics, Volume 53, Issue 4, April 2026.
Abstract Background: Radiomics has shown potential for quantitative characterization of tumors in molecular imaging; however, its clinical translation in theranostic 177Lu SPECT/CT remains limited due to poor robustness of extracted features to reconstruction variability and partial volume effects.
Mohammad Saber Azimi, Maryam Cheraghi, Mohammad Ali Ghodsi Rad, Mohadeseh Bayat, Maryam Alhashim, Habibollah Dadgar, Mahmoud Alabedi, Nahid Ibrahim, Enas Alwuhaib, Hossein Arabi, Arman Rahmim, Habib Zaidi   +11 more
wiley   +1 more source

Cutting‐edge advances in bicyclic peptide‐based radiotracers for cancer imaging and theranostics

VIEW, Volume 7, Issue 2, April 2026.
Bicyclic peptides, a burgeoning subset of bicyclic macrocycles, are characterized by two loops stabilized through three linkages of the central chemical scaffolds. As an immense potential platform for radiotracers development, bicyclic peptide‐based radiotracers have yielded encouraging results in preclinical and clinical trial studies.
Hengyi Ou, Xiaobo Wang, Fei Kang
wiley   +1 more source

Role of ¹⁸F-AlF-NOTATATE PET/CT in selecting pediatric neuroblastoma candidates for ¹⁷⁷Lu-DOTATATE peptide receptor radionuclide therapy. [PDF]

Front Med (Lausanne)
Background Neuroblastoma is the most common extracranial solid tumor in children. Peptide receptor radionuclide therapy (PRRT) is a treatment modality with great potential, however, the predictive indicators for its efficacy remain unclear.
Liu Y, Sun Y, Zuo D, Wang H, Zheng F, Wang J, Sun X.   +6 more
europepmc   +2 more sources

Terapia com [177Lu – Dota0 – Tyr3]–Octreotate (177Lu-Dotatate) em Pacientes com Tumores Avançados de Origem Neuroendócrino: Experiência Inicial e Resultados Preliminares

Revista Ciencias de la Salud, 2017
Objetivo: mostrar a experiência inicial e os resultados preliminares da terapia com [177Lu – Dota0 – Tyr3] –Octreotate (177Lu-Dotatate) em pacientes tratados na nossa instituição, devido a que a experiência derivada desta prática em países latino ...
Víctor Marín Oyaga, Claudia Gutiérrez Villamil, Arturo Mejía López, Alex Valenzuela Rincón, Gabriel Sánchez de Guzmán, José Sinay Arévalo Leal   +5 more
doaj   +1 more source

Searching for Synergy : Radiosensitization of 177Lu-DOTATATE

, 2022
Cancers presents a major health challenge, and there is a pressing need to develop new therapeutic strategies. Surgery, chemotherapy and radiation are the most commonly used treatments for cancer today. Radiation can be given as targeted radionuclide therapy (TRT), i.e., systemic administration of a radiolabeled cancer-targeting molecule.
openaire   +1 more source